Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 241301, 13 pages
http://dx.doi.org/10.1155/2015/241301
Research Article

Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis

1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia
2P.A. Herzen Moscow Cancer Research Institute, Ministry of Healthcare of the Russian Federation, Moscow 125284, Russia
3Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Kiev 03680, Ukraine
4Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 17177 Stockholm, Sweden
5Institute of Urology, National Academy of Medical Sciences of Ukraine, Kiev 04053, Ukraine
6Department of Molecular Biology, Kurchatov NBIC Centre NRC “Kurchatov Institute”, Moscow 123182, Russia
7Bioinformatics Infrastructure for Life Sciences, Science for Life Laboratory, Karolinska Institute, 17177 Stockholm, Sweden

Received 9 February 2015; Revised 11 July 2015; Accepted 14 July 2015

Academic Editor: Stamatios Theocharis

Copyright © 2015 Alexey A. Dmitriev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France, 2012, http://globocan.iarc.fr/.
  2. H. Ahmadi and S. Daneshmand, “Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes,” Patient Related Outcome Measures, vol. 5, pp. 63–70, 2014. View at Publisher · View at Google Scholar
  3. M. Katsogiannou, H. Ziouziou, S. Karaki, C. Andrieu, M. H. de Villeneuve, and P. Rocchi, “The hallmarks of castration-resistant prostate cancers,” Cancer Treatment Reviews, vol. 41, no. 7, pp. 588–597, 2015. View at Publisher · View at Google Scholar
  4. A. D. Grigore, E. Ben-Jacob, and M. C. Farach-Carson, “Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?” Frontiers in Oncology, vol. 5, article 37, 2015. View at Publisher · View at Google Scholar
  5. V. J. Gnanapragasam, “Molecular markers to guide primary radical treatment selection in localized prostate cancer,” Expert Review of Molecular Diagnostics, vol. 14, no. 7, pp. 871–881, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Nazim and F. Abbas, “Role of surgery in locally advanced prostate cancer,” Pakistan Journal of Medical Sciences, vol. 31, no. 3, pp. 710–716, 2015. View at Publisher · View at Google Scholar
  7. E. F. Faria, B. F. Chapin, R. L. Muller, R. D. Machado, R. B. Reis, and S. F. Matin, “Radical prostatectomy for locally advanced prostate cancer: current status,” Urology, vol. 86, no. 1, pp. 10–15, 2015. View at Publisher · View at Google Scholar
  8. J. Sullivan, R. Kopp, K. Stratton et al., “An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality,” British Journal of Cancer, vol. 113, no. 1, pp. 166–172, 2015. View at Publisher · View at Google Scholar
  9. M. Danilewicz, O. Stasikowska-Kanicka, and M. Wagrowska-Danilewicz, “Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer,” Polish Journal of Pathology, vol. 66, no. 1, pp. 44–48, 2015. View at Publisher · View at Google Scholar
  10. S. I. Berndt, Z. Wang, M. Yeager et al., “Two susceptibility loci identified for prostate cancer aggressiveness,” Nature Communications, vol. 6, p. 6889, 2015. View at Google Scholar
  11. A. B. Gutman and E. B. Gutman, “An ‘acid’ phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland,” The Journal of Clinical Investigation, vol. 17, no. 4, pp. 473–478, 1938. View at Publisher · View at Google Scholar
  12. T. Bhavsar, P. McCue, and R. Birbe, “Molecular diagnosis of prostate cancer: are we up to age?” Seminars in Oncology, vol. 40, no. 3, pp. 259–275, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Y. Kong and J. Byun, “Emerging roles of human prostatic acid phosphatase,” Biomolecules and Therapeutics, vol. 21, no. 1, pp. 10–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Chou, J. M. Croswell, T. Dana et al., “Screening for prostate cancer: a review of the evidence for the U.S. Preventive services task force,” Annals of Internal Medicine, vol. 155, no. 11, pp. 762–771, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ferro, D. Bruzzese, S. Perdonà et al., “Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml,” PLoS ONE, vol. 8, no. 7, Article ID e67687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. E. Rosenberg, T. Y. Prudnikova, G. V. Gerashchenko, E. V. Grigorieva, and V. I. Kashuba, “Search for genes—potential markers of aggressiveness and metastasis for human prostate cancer,” Biopolymers and Cell, vol. 29, no. 6, pp. 499–505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C. A. Iacobuzio-Donahue, “Epigenetic changes in cancer,” Annual Review of Pathology: Mechanisms of Disease, vol. 4, pp. 229–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Singal, L. Ferdinand, I. M. Reis, and J. J. Schlesselman, “Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease,” Oncology Reports, vol. 12, no. 3, pp. 631–637, 2004. View at Google Scholar · View at Scopus
  19. J. Pan, Y. Chen, C. Mo et al., “Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis,” PLoS ONE, vol. 9, no. 3, Article ID e92815, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Sandoval, L. Peiró-Chova, F. V. Pallardó, and J. L. García-Giménez, “Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities,” Expert Review of Molecular Diagnostics, vol. 13, no. 5, pp. 457–471, 2013. View at Publisher · View at Google Scholar
  21. S. H. Strand, T. F. Orntoft, and K. D. Sorensen, “Prognostic DNA methylation markers for prostate cancer,” International Journal of Molecular Sciences, vol. 15, no. 9, pp. 16544–16576, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Daniunaite, S. Jarmalaite, N. Kalinauskaite et al., “Prognostic value of RASSF1 promoter methylation in prostate cancer,” Journal of Urology, vol. 192, no. 6, pp. 1849–1855, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Woodson, K. J. O'Reilly, D. E. Ward et al., “CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease,” Epigenetics, vol. 1, no. 4, pp. 183–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Chiam, C. Ricciardelli, and T. Bianco-Miotto, “Epigenetic biomarkers in prostate cancer: current and future uses,” Cancer Letters, vol. 342, no. 2, pp. 248–256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Weiss, S. Cottrell, J. Distler et al., “DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy,” The Journal of Urology, vol. 181, no. 4, pp. 1678–1685, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Maldonado, M. Brait, M. Loyo et al., “GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer,” Journal of Urology, vol. 192, no. 5, pp. 1542–1548, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Zhang, H. Jiao, X. Zhang et al., “Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer,” Molecular Medicine Reports, vol. 12, no. 1, pp. 141–146, 2015. View at Publisher · View at Google Scholar
  28. L. Richiardi, V. Fiano, C. Grasso et al., “Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer,” PLoS ONE, vol. 8, no. 7, Article ID e68162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Li, R. Wang, Z. Yan, L. Bai, and Z. Sun, “High accordance in prognosis prediction of colorectal cancer across independent datasets by multi-gene module expression profiles,” PLoS ONE, vol. 7, no. 3, Article ID e33653, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Tsunashima, Y. Naoi, N. Kagara et al., “Construction of multi-gene classifier for prediction of response to and prognosis after neoadjuvant chemotherapy for estrogen receptor positive breast cancers,” Cancer Letters, vol. 365, no. 2, pp. 166–173, 2015. View at Publisher · View at Google Scholar
  31. G. V. Gerashchenko, O. O. Bogatyrova, E. E. Rudenko et al., “Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas,” Experimental Oncology, vol. 32, no. 2, pp. 71–75, 2010. View at Google Scholar · View at Scopus
  32. V. V. Gordiyuk, “Genetic and epigenetic changes of genes on chromosome 3 in human urogenital tumors,” Biopolymers and Cell, vol. 27, no. 1, pp. 25–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. V. I. Kashuba, I. Y. Skrypkina, D. V. Saraev et al., “Identification of changes in gene loci potentially associated with cervical cancer using NotI microarrays,” Ukrain'skyi Biokhimichnyi Zhurnal, vol. 78, no. 2, pp. 113–120, 2006. View at Google Scholar · View at Scopus
  34. L. B. Hesson, W. N. Cooper, and F. Latif, “Evaluation of the 3p21.3 tumour-suppressor gene cluster,” Oncogene, vol. 26, no. 52, pp. 7283–7301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Ciriello, M. L. Miller, B. A. Aksoy, Y. Senbabaoglu, N. Schultz, and C. Sander, “Emerging landscape of oncogenic signatures across human cancers,” Nature Genetics, vol. 45, no. 10, pp. 1127–1133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Ji, J. D. Minna, and J. A. Roth, “3p21.3 tumor suppressor cluster: prospects for translational applications,” Future Oncology, vol. 1, no. 1, pp. 79–92, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. J. H. Smith, J. Xian, M. Richardson, K. A. Johnstone, and P. Rabbitts, “Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours,” Oncogene, vol. 21, no. 29, pp. 4521–4529, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Li, A. Protopopov, F. Wang et al., “NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 16, pp. 10724–10729, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Maniatis, E. F. Fritsch, and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA, 1982.
  40. T. L. Dunwell, L. B. Hesson, T. Pavlova et al., “Epigenetic analysis of childhood acute lymphoblastic leukemia,” Epigenetics, vol. 4, no. 3, pp. 185–193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. V. V. Gordiyuk, G. V. Gerashchenko, I. Y. Skrypkina et al., “Identification of chromosome 3 epigenetic and genetic abnormalities and gene expression changes in ovarian cancer,” Biopolymers and Cell, vol. 24, no. 4, pp. 323–332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Haraldson, V. I. Kashuba, A. A. Dmitriev et al., “LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication,” Biochimie, vol. 94, no. 5, pp. 1151–1157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. A. A. Dmitriev, V. I. Kashuba, K. Haraldson et al., “Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays,” Epigenetics, vol. 7, no. 5, pp. 502–513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. V. N. Senchenko, G. S. Krasnov, A. A. Dmitriev et al., “Differential expression of CHL1 gene during development of major human cancers,” PLoS ONE, vol. 6, no. 3, Article ID e15612, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. G. S. Krasnov, N. Y. Oparina, A. A. Dmitriev et al., “RPN1, a new reference gene for quantitative data normalization in lung and kidney cancer,” Molecular Biology, vol. 45, no. 2, pp. 211–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Campbell and Y. Ying, Learning with Support Vector Machines, Morgan & Claypool Publishers, San Rafael, Calif, USA, 2011.
  47. R. Nisbet, J. Elder, and G. Miner, Handbook of Statistical Analysis and Data Mining Applications, Academic Press, Burlington, Mass, USA, 2009.
  48. A. Alexeyenko, W. Lee, M. Pernemalm et al., “Network enrichment analysis: extension of gene-set enrichment analysis to gene networks,” BMC Bioinformatics, vol. 13, no. 1, article 226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Alexeyenko and E. L. L. Sonnhammer, “Global networks of functional coupling in eukaryotes from comprehensive data integration,” Genome Research, vol. 19, no. 6, pp. 1107–1116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Kanehisa, S. Goto, S. Kawashima, and A. Nakaya, “The KEGG databases at GenomeNet,” Nucleic Acids Research, vol. 30, no. 1, pp. 42–46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Ruepp, B. Waegele, M. Lechner et al., “CORUM: the comprehensive resource of mammalian protein complexes—2009,” Nucleic Acids Research, vol. 38, pp. D497–D501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. L. A. Bovolenta, M. L. Acencio, and N. Lemke, “HTRIdb: an open-access database for experimentally verified human transcriptional regulation interactions,” BMC Genomics, vol. 13, article 405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. E. R. Zabarovsky, R. Gizatullin, R. M. Podowski et al., “NotI clones in the analysis of the human genome,” Nucleic Acids Research, vol. 28, no. 7, pp. 1635–1639, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. G. V. Gerashchenko, V. V. Gordiyuk, I. Y. Skrypkina et al., “Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer,” Ukrainskiĭ Biokhimicheskiĭ Zhurna, vol. 81, no. 4, pp. 81–87, 2009. View at Google Scholar · View at Scopus
  56. V. N. Senchenko, N. P. Kisseljova, T. A. Ivanova et al., “Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer,” Epigenetics, vol. 8, no. 4, pp. 409–420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. A. A. Dmitriev, E. E. Rudenko, A. V. Kudryavtseva et al., “Epigenetic alterations of chromosome 3 revealed by noti-microarrays in clear cell renal cell carcinoma,” BioMed Research International, vol. 2014, Article ID 735292, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. A. G. Kondratov, S. M. Kvasha, L. A. Stoliar et al., “Alterations of the WNT7A gene in clear cell renal cell carcinomas,” PLoS ONE, vol. 7, no. 10, Article ID e47012, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. V. Kashuba, A. A. Dmitriev, G. S. Krasnov et al., “Noti microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer,” International Journal of Molecular Sciences, vol. 13, no. 10, pp. 13352–13377, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Li, Y. Du, D. Zhang et al., “Identification of novel DNA methylation markers in colorectal cancer using MIRA-based microarrays,” Oncology Reports, vol. 28, no. 1, pp. 99–104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. Z.-Q. Lian, Q. Wang, W.-P. Li, A.-Q. Zhang, and L. Wu, “Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels,” International Journal of Oncology, vol. 41, no. 2, pp. 629–638, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. J. U. Kang, S. H. Koo, K. C. Kwon, J. W. Park, and J. M. Kim, “Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung,” BMC Cancer, vol. 9, article 237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. T. V. Pavlova, V. I. Kashuba, O. V. Muravenko et al., “Use of NotI microarrays in analysis of epigenetic and structural changes in epithelial tumor genomes by the example of human chromosome 3,” Molecular Biology, vol. 43, no. 2, pp. 313–320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. B. S. Taylor, N. Schultz, H. Hieronymus et al., “Integrative genomic profiling of human prostate cancer,” Cancer Cell, vol. 18, no. 1, pp. 11–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Bastola, Y. Stratton, E. Kellner et al., “Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy,” PLoS ONE, vol. 8, no. 7, Article ID e70030, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. M. A. Chetram, D. A. Bethea, V. A. Odero-Marah, A. S. Don-Salu-Hewage, K. J. Jones, and C. V. Hinton, “ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells,” Molecular and Cellular Biochemistry, vol. 376, no. 1-2, pp. 63–71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. X.-Y. Yang, X.-G. Lai, Y. Zhang, J.-M. Pei, A.-G. Yang, and S.-S. Zhou, “siRNA-mediated silencing of ClC-2 gene inhibits proliferation of human U-87 glioma cells,” Ai Zheng, vol. 25, no. 7, pp. 805–810, 2006. View at Google Scholar · View at Scopus
  68. C.-Y. Chang, S.-C. Lin, W.-H. Su, C.-M. Ho, and Y.-S. Jou, “Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma,” Oncogene, vol. 31, no. 21, pp. 2640–2652, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Lehto, S. Laitinen, G. Chinetti et al., “The OSBP-related protein family in humans,” The Journal of Lipid Research, vol. 42, no. 8, pp. 1203–1213, 2001. View at Google Scholar · View at Scopus
  70. R. D. M. Steenbergen, M. Ongenaert, S. Snellenberg et al., “Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis,” Journal of Pathology, vol. 231, no. 1, pp. 53–62, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Miyamoto, T. Fukutomi, S. Akashi-Tanaka et al., “Identification of 20 genes aberrantly methylated in human breast cancers,” International Journal of Cancer, vol. 116, no. 3, pp. 407–414, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Shiraishi, C. Zhou, T. Aoki et al., “TBP-interacting protein 120B (TIP120B)/cullin-associated and neddylation-dissociated 2 (CAND2) inhibits SCF-dependent ubiquitination of myogenin and accelerates myogenic differentiation,” Journal of Biological Chemistry, vol. 282, no. 12, pp. 9017–9028, 2007. View at Publisher · View at Google Scholar